Check-Cap Ltd. (NASDAQ:CHEK) posted its quarterly earnings data on Thursday. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.01, MarketWatch Earnings reports.

Check-Cap (NASDAQ:CHEK) traded down 4.00% during trading on Friday, hitting $1.68. 42,663 shares of the company traded hands. The stock has a 50-day moving average price of $1.85 and a 200-day moving average price of $2.06. The firm’s market capitalization is $26.26 million. Check-Cap has a 12-month low of $1.65 and a 12-month high of $2.95.

ILLEGAL ACTIVITY WARNING: “Check-Cap Ltd. (NASDAQ:CHEK) Posts Earnings Results, Misses Expectations By $0.01 EPS” was first published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/check-cap-ltd-nasdaqchek-posts-earnings-results-misses-expectations-by-0-01-eps.html.

A number of analysts have recently issued reports on CHEK shares. Zacks Investment Research downgraded shares of Check-Cap from a “buy” rating to a “hold” rating in a report on Friday, June 16th. ValuEngine cut shares of Check-Cap from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. HC Wainwright set a $6.00 target price on shares of Check-Cap and gave the company a “buy” rating in a research note on Friday. Finally, Maxim Group reissued a “buy” rating on shares of Check-Cap in a research note on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.